Peer-reviewed veterinary case report
Clinical signs of canine CD8+ and CD4-CD8- T-cell lymphomas
By Harris, Lauren J et al.·Published in Veterinary and comparative oncology·2020·Department of Microbiology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical features of canine nodal T-cell lymphomas classified as CD8+ or CD4-CD8- by flow cytometry.
- Species:
- dog
Plain-English summary
A group of dogs diagnosed with T-cell lymphoma, a type of cancer affecting the lymph nodes, showed different symptoms based on their specific type. Dogs with the CD8 type often had skin lesions, while those with the CD4-CD8 type experienced issues like enlarged lymph nodes and high calcium levels. Unfortunately, both groups had aggressive forms of the disease, with average survival times of about 198 days for CD8 and 145 days for CD4-CD8. The size of the cancer cells also played a role, with larger cells linked to shorter survival times. Treatment options were not detailed, but understanding the type of lymphoma can help guide care.
People also search for: dog lymphoma symptoms · T-cell lymphoma in dogs · dog skin lesions cancer · dog lymph node swelling treatment
Abstract
Canine T-cell lymphoma (TCL) encompasses a heterogeneous group of diseases with variable clinical presentation, cytomorphology, immunophenotype, and biologic behaviour. The most common types of TCL in dogs involving peripheral lymph nodes include indolent T-zone lymphoma (TZL) and biologically aggressive peripheral T-cell lymphoma (PTCL). TCL phenotypes can be categorized by expression of the surface antigen molecules CD4 and CD8. The majority of TCL cases are CD4, with far fewer cases being CD8or CD4CD8. The clinical features of CD4TCLs have been previously described. The less common TCL phenotypes, however, are poorly characterized with little to no information about prognosis. In this retrospective study, we describe and correlate the presenting clinical signs, flow cytometry, and outcomes of 119 dogs diagnosed with nodal, non-TZL, CD8or CD4CD8TCL by flow cytometry. Skin lesions present at the time of diagnosis were more commonly observed in the CD8TCL group. Mediastinal enlargement and/or hypercalcemia were more commonly seen in the CD4CD8TCL group. Dogs with either CD8or CD4CD8TCLs had aggressive clinical disease with median overall survival (OS) times of 198 days and 145 days, respectively. In both groups, neoplastic cell size determined by flow cytometry ranged from small to large, and large cell size was associated with shorter OS times (median OS = 61 days). Cases classified as small cell had a median OS of 257 days. Expression levels of major histocompatibility complex (MHC) class II and CD5 were highly variable among cases but were not prognostically significant in this group of patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31951040/